The brokerage believes that Indegene has entered FY27 with a stronger and more diversified growth pipeline, supported by continued expansion within existing accounts, increasing contribution from clients outside the top 20 and traction in GenAI-led solutions across both commercial and medical affairs.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.